Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimodulin - Biotest

Next Previous
Drug Profile

Trimodulin - Biotest

Alternative Names: BT 588; BT086; IgM concentrate - Biotest; Trimodulia

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest AG
  • Class Anti-infectives; Anti-inflammatories; Antivirals; Polyclonal antibodies
  • Mechanism of Action Endotoxin inhibitors; Immunostimulants; Phagocyte stimulants; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; COVID 2019 infections

Most Recent Events

  • 08 Jun 2025 Biotest terminates a phase-III trial in COVID-2019 infections (Adjunctive treatment) in Hungary, France, Brazil, Spain, Turkey, South Africa, Slovakia, Portugal, Lithuania, Latvia, Germany, Belgium, Australia, Argentina (IV) due to unacceptable delay of trial completion low recruitment rate (NCT05531149)
  • 20 Jun 2023 Phase-III clinical trials in Community-acquired pneumonia (Adjunctive treatment) in USA, Czech Republic, Belgium (IV) (NCT05722938)
  • 10 Feb 2023 Biotest AG plans a phase III trial for Community-acquired pneumonia (Adjunctive therapy, In adults, In the elderly) in March 2023 (IV, Infusion) (NCT05722938)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top